IPM Take
Rare cancers are where sloppy diagnostic pathways do the most damage. FGFR2 fusions and rearrangements define a treatment-relevant subgroup in cholangiocarcinoma, but only patients who receive adequate molecular testing can enter it. Another approval strengthens the argument that comprehensive profiling in advanced biliary cancer should be a pathway requirement, not a centre-by-centre luxury.
Executive Summary
FDA approved lirafugratinib (Lyrfigtu) on 23 September for adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harbouring an FGFR2 gene fusion or other rearrangement. The approval was based on REFOCUS, a multicenter, open-label, single-arm trial of 116 FGFR inhibitor-naive patients previously treated with chemotherapy or chemoimmunotherapy. Objective response rate was 46%, with median duration of response of 11.8 months. The label includes warnings for ocular toxicity, hyperphosphatemia and soft-tissue mineralisation.
Why it matters
- Patients / advocates: A rare molecular alteration can now open another targeted treatment pathway after standard therapy.
- Diagnostics / pathology: FGFR2 testing must happen before the patient exhausts the window for treatment.
- Clinicians: The approval expands an increasingly molecular treatment landscape in biliary cancer.
- Payers: Reimbursement for the medicine without reliable reimbursement for molecular testing is an incomplete access strategy.
Cholangiocarcinoma is becoming a test of whether precision oncology is willing to do the boring part.
Not drug discovery.
Testing.
Lirafugratinib now joins the targeted treatment landscape for adults whose advanced cholangiocarcinoma carries an FGFR2 fusion or rearrangement. In REFOCUS, 46% of patients responded, and median response duration was almost a year.
For a rare, aggressive cancer after prior systemic therapy, that matters.
But the FDA label contains a condition before the treatment even begins: the tumour has to have the alteration.
That sounds obvious. In practice, it is where precision pathways fracture.
Comprehensive genomic profiling is not uniformly available. Tissue can be limited. Referral can be late. Testing may depend on hospital budget, insurer policy, country, laboratory access or whether the treating clinician works inside a molecularly mature centre.
Every new genotype-defined approval makes those inequalities less defensible.
There is another reason to keep the story grounded. REFOCUS is a single-arm study. The response signal is strong enough for approval, but it is not the same evidentiary architecture as a randomized survival comparison. Toxicity also requires specialist attention, particularly ocular effects and hyperphosphatemia.
Still, the direction is unmistakable.
Biliary cancer care is moving away from a purely anatomical diagnosis toward a molecular treatment map.
The drug is ready.
The question is whether the testing pathway is.
